Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ADL-2-1294 (Adolor).

G D Wheeler1

  • 1editor@greyowltutor.com

Idrugs : the Investigational Drugs Journal
|July 28, 2005
PubMed
Summary
This summary is machine-generated.

Adolor is developing topical and ophthalmic formulations of loperamide (ADL-2-1294) for inflammatory pain and pruritus. Clinical trials are ongoing for burns, wounds, and eye conditions, with promising preclinical results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury.

Spinal cord·2002
Same author

Electrical stimulation: can it increase muscle strength and reverse osteopenia in spinal cord injured individuals?

Archives of physical medicine and rehabilitation·2000
Same author

The effects of surface anaesthesia on the autonomic dysreflexia response during functional electrical stimulation.

Spinal cord·1997
Same author

Hormonal responses to graded-resistance, FES-assisted strength training in spinal cord-injured.

Spinal cord·1996
Same author

Functional and therapeutic benefits of electrical stimulation after spinal injury.

Current opinion in neurology·1995
Same author

Physiological correlates of simulated wheelchair racing in trained quadriplegics.

Canadian journal of applied physiology = Revue canadienne de physiologie appliquee·1995
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Dermatology
  • Ophthalmology

Background:

  • Loperamide (ADL-2-1294), an antidiarrheal compound, acts as a peripheral opiate receptor agonist.
  • Adolor is exploring novel topical and ophthalmic formulations of loperamide.

Purpose of the Study:

  • To evaluate the efficacy and safety of loperamide formulations for treating inflammatory pain and pruritus.
  • To investigate loperamide's potential in conditions such as burns, wounds, and eye diseases.

Main Methods:

  • Phase I and II clinical trials for topical and ophthalmic formulations.
  • Preclinical studies in animal models of inflammatory pain.
  • Assessment of safety, tolerance, pharmacokinetics, and topical sensitivity.

Main Results:

Related Experiment Videos

  • Positive results from Phase I trials of the topical formulation in burn patients.
  • Preclinical studies demonstrated efficacy in animal models of inflammatory pain.
  • Ongoing Phase II trials for topical and ophthalmic formulations.

Conclusions:

  • Loperamide (ADL-2-1294) formulations show potential for treating inflammatory pain and pruritus.
  • Further clinical development is warranted for various dermatological and ophthalmological conditions.
  • Licensing agreements indicate commercial interest in topical ADL-2-1294.